Original paper

Economic evaluation of an internet-based preventive cognitive therapy with minimal therapist support for recurrent depression: results of a randomized controlled trial

Nicola S. Klein, MSc,1 Claudi L.H. Bockting, PhD,2 Ben Wijnen, PhD,3 Gemma D. Kok, PhD,5 Evelien van Valen, MSc,6 Heleen Riper, PhD,7-9 Pim Cuijpers, PhD,7-8 Jack Dekker, PhD,7,10 Colin van der Heiden,11,12 PhD, Huibert Burger, MD PhD,13 Filip Smit, PhD3,7,8

1Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, The Netherlands
2Department of Psychiatry, Academic Medical Center, Amsterdam, The Netherlands
3Department of Public Mental Health, Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, The Netherlands
4CAPHRI School for Public Health and Primary Care, Department of Health Services Research, Maastricht University, Maastricht, The Netherlands
5Ambulante Forensische Psychiatrie Noord (AFPN), GGZ Drenthe, Emmen, The Netherlands
6Department of Geriatrics, University Medical Center Utrecht, Utrecht, The Netherlands
7Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit, Amsterdam, The Netherlands
8Amsterdam Public Health, VU University Medical Center, Amsterdam, The Netherlands
9GGZ inGeest, Amsterdam, The Netherlands
10Research Department Arkin Mental Health Institute, Amsterdam, The Netherlands
11Department of Psychology, Education and Child Studies, Erasmus University Rotterdam, Rotterdam, The Netherlands
12PsyQ Mental Health Care Center, Rotterdam, The Netherlands
Abstract:

Background: Major Depressive Disorder (MDD) is highly recurrent and has a significant disease burden. Although the effectiveness of internet-based interventions has been established for the treatment of acute MDD, little is known about their cost-effectiveness, especially in recurrent MDD.

Objectives: Our aim was to evaluate the cost-effectiveness and cost-utility of an internet-based relapse prevention program (Mobile Cognitive Therapy, M-CT).

Methods: The economic evaluation was performed alongside a single-blind parallel group randomized controlled trial. Participants were recruited via media, general practitioners, and
mental health care institutions. In total, 288 remitted individuals with a history of recurrent depression were eligible, of whom 264 were randomly allocated to M-CT with minimal therapist support added to Treatment As Usual (TAU) or TAU alone. M-CT comprised eight online lessons and participants were advised to complete one lesson per week. The economic evaluation was performed from a societal perspective with a 24-month time horizon. The health outcomes were number of depression-free days based on DSM-IV criteria assessed with the Structured Clinical Interview for DSM-IV axis I disorders by blinded interviewers after 3, 12, and 24 months. Quality-Adjusted Life Years (QALYs) were self-assessed with the EQ-5D-3L. Costs were assessed with the Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TiC-P). Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves were used to assess the probability that M-CT is cost-effective compared to TAU.

**Results:** Costs were higher and outcomes slightly better for M-CT. The incremental costs were €179 per depression-free day and €230,816 per QALY. The cost-effectiveness acceptability curves suggested that for depression-free days high investments have to be made to reach an acceptable probability that M-CT is cost-effective compared to TAU. Regarding QALYs, considerable investments have to be made but the probability that M-CT is cost-effective compared to TAU does not rise above 40%.

**Conclusions:** The results suggest that adding M-CT to TAU is not effective and cost-effective compared to TAU alone. Adherence rates were similar to other studies and therefore do not explain this finding. The participants scarcely booked additional therapist support, resulting in 17.3 minutes of mean total therapist support. More studies are needed to examine the cost-effectiveness of internet-based interventions with respect to long-term outcomes and the role and optimal dosage of therapist support. Overall, more research is needed on scalable and cost-effective interventions that can reduce the burden of recurrent MDD.
Trial registration: trialregister.nl NTR2503
Introduction

In 2016, an estimated 268 million individuals worldwide were affected with a depressive disorder [1]. Major Depressive Disorder (MDD) is a highly recurrent disorder [2] with a substantial disease burden [1,3] and formidable economic costs due to health care utilization and productivity losses [4-7].

To alleviate the burden of MDD, psychological interventions and/or antidepressants (ADs) are recommended for the acute phase of MDD and further as continuation/maintenance therapy to prevent relapse and recurrence [8]. However, health care resources are limited and many individuals fail to seek treatment [9-12]. Because of their flexible and accessible nature, internet-based interventions could be a viable cost-effective solution that reaches a large number of ‘at risk’ individuals. The effectiveness of internet-based interventions in acute and residual MDD has been established [13-18], with small to moderate effect sizes for interventions with therapist support and higher effect sizes with therapist support [e.g., 13,15]. To date, only one study examined the long-term effects of an internet-based relapse prevention program [19] and no study examined its cost-effectiveness. Thus, little is known about the cost-effectiveness of internet-based relapse prevention for recurrent MDD. More information is needed on the health impact and economic costs to inform policy makers and health care providers.

In our Randomized Controlled Trial (RCT), we examined the clinical effectiveness of an internet-based relapse prevention program (Mobile Cognitive Therapy, M-CT) added to Treatment As Usual (TAU) compared to TAU alone in remitted individuals with recurrent MDD. Results showed that M-CT added to TAU was slightly but not significantly superior to TAU alone after 24 months in terms of cumulative relapse/recurrence rate, number of depressive relapses, and depressive symptoms [20]. In the current study, we evaluated the cost-effectiveness and cost-utility of M-CT to see if the economic case could be made for this
low cost and highly scalable intervention that was added to TAU. We hypothesize that M-CT added to TAU is cost-effective compared to TAU alone as it might generate slightly better health outcomes and thereby lower costs for other mental health services.

Methods

Study design
The economic evaluation was performed alongside a single-blind parallel group two-arm RCT in which 288 participants aged between 18 and 65 years were eligible of whom 264 were randomized to either M-CT added to TAU or TAU alone ([www.trialregister.nl](http://www.trialregister.nl), identifier: NTR2503, approved by METIGG: an independent medical ethics committee). The economic evaluation was conducted and reported according to the Consolidated Health Economic Evaluation Reporting Standards statement (CHEERS). The study design and results are described in detail elsewhere [20,21], but will be summarized briefly.

Participants and procedure
The participants were recruited via media, general practitioners, and mental health care services and were included between mid-September 2010 and August 2013 after providing a written informed consent. To be included, the following criteria had to be met: 1. A history of at least two depressive episodes according to the DSM-IV assessed with the Structured Clinical Interview for DSM-IV Disorders (SCID-I) [22] of which the latest episode occurred within the last two years. 2. Currently remitted for at least 2 months according to the SCID-I and a score of \( \leq 10 \) on the Hamilton Rating Scale for Depression (HRSD) [23]. Exclusion criteria were: current or past (hypo) mania, a bipolar or psychotic disorder, alcohol or drugs abuse, or a predominant anxiety disorder. Independent psychologists or research assistants
interviewed the potential participants for inclusion and exclusion criteria. Our initial criterion of having experienced two depressive episodes within 5 years was discarded, as individuals with multiple episodes over a longer period of time are also at risk [24]. We examined whether this affected our primary outcomes but this was not the case.

Randomization and masking

Randomization was planned to be stratified by type of aftercare and number of depressive episodes, but eventually simple randomization was carried out due to a programming error. The participants were randomized (allocation ratio 1:1) by an independent researcher not otherwise involved in the study who was masked for clinical characteristics and who used computer-generated numbers in STATA. An independent researcher not involved in the follow-up interviews assigned the participants to the treatment conditions. The participants were not blinded to treatment allocation due to the nature of the intervention. The interviewers were unaware of the participants’ treatment allocation and the participants were instructed not to inform the interviewer of their treatment allocation. The assessor was replaced by another independent assessor in case the randomization was broken.

Interventions

M-CT is based on Preventive Cognitive Therapy (PCT) [25], a face-to-face therapy that protects against relapse/recurrence in remitted individuals [26-28]. Bockting and Van Valen developed the content of M-CT [29] and it was built into the E-platform of the Trimbos Institute. Participants from previous relapse prevention studies and the Patients’ Association for Depression were involved in the development of the research question, outcome measures, the design, development, and implementation of M-CT. The content of the program remained unaltered during the evaluation period and logfile analysis was used to monitor the use of the
intervention. The program was free of charge for the participants and an independent researcher provided participants with usernames and passwords to log in. M-CT comprised of eight online modules with minimal therapist support and continued mobile mood monitoring using text messages. The participants were advised to work on one lesson each week and were offered a minimum of two and a maximum of four telephone contacts with a therapist (maximum duration: 30 minutes per contact). Two therapist contacts were pre-booked and two optional contacts could be booked by the participants additionally. Participating therapists were supervised by an experienced clinical psychologist. The primary task of the therapists was to work through the M-CT program. The participants received a reminder per e-mail or text message if they did not log into the website for 6 weeks. Feedback from the participants on the intervention was obtained by giving them the opportunity to evaluate each specific lesson. Participants randomized to M-CT and TAU continued to receive usual care, which could include for example ADs, counseling, or no care.

**Costs and unit prices**

The economic evaluation was conducted from a societal perspective, implying that costs both inside and outside the health care sector were assessed. Health care costs were related to medication use and inpatient, outpatient, and primary care. Costs directly related to the M-CT intervention included costs of training and supervision of therapists during the study, the duration of contacts between participants and therapists (telephone and email contact), and ICT-related costs. The last category mainly consisted of costs related to developing, upgrading, and maintaining the M-CT website. In addition, various types of costs outside the health care sector were examined. Patient and family costs included informal care (i.e., the monetary valuation of time invested by relatives or acquaintances in helping or assisting the participant), travel expenses, and (psychiatric) home care. Furthermore, costs of productivity
losses due to illness-related absence from work were estimated and costs related to changes in efficiency while at work and changes in the amount of voluntary (unpaid) work conducted by the participants. Costs of productivity losses were estimated with the friction cost method [30]. This method takes the employer’s perspective and calculates the time (the friction period) until another employee has replaced the worker that is absent.

Information on health care consumption and productivity losses was collected with the Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness (TiC-P) [31]. This questionnaire was administered online to all participants in 3-month intervals, starting at baseline. Since there was variation in the maximum number of days medication use could be filled out by the participants, we extrapolated all medication use to 3 months. In order to facilitate comparisons with other economic evaluations, unit prices, i.e., the price of one unit of each included cost type, were based on Dutch standard prices for the year 2014 [32]. Full economic cost prices of used resources were computed when standard prices were not available.

**Outcomes**

The economic evaluation comprised a cost-effectiveness and a cost-utility analysis. The health outcome measure of the cost-effectiveness analysis was the number of depression-free days based on DSM-IV criteria assessed with a telephone version of the SCID-I after 3, 12, and 24 months. QALYs were used as health outcome measure of the cost-utility analysis. The QALY is a health measure that combines quality of life and the amount of time spent in a health condition, where one QALY is equal to 1 year lived in perfect health. The quality component of the QALY was derived from the EQ-5D-3L administered online in 3-month intervals starting from baseline [33] by using the algorithm of Dolan to obtain utilities for specific health states [34]. The EQ-5D-3L is a commonly applied self-administered instrument that
measures the generic health status and consists of five questions covering the following five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Both costs and health outcomes were discounted at 1.5% for health outcomes and 4% for costs according to the Dutch guidelines [35].

**Statistical analysis**

The power calculation of the primary outcome is described elsewhere [20,21]. Since the study was only powered to detect differences in health outcomes and not in costs, as in most economic evaluations, we used probabilistic and medical decision-making techniques to draw inferences about the cost-effectiveness. The clinical results were reported according to the CONSORT statement (Multimedia Appendix 1). The intention-to-treat principle was used, in which all participants were analysed according to their randomized condition, irrespective of their actual treatment.

In our main analysis, we used multiple imputations by chained equations with predictive mean matching to account for missing data. The use of this technique may avoid bias associated with complete case analyses and makes optimal use of available data. Baseline variables predictive of clinical and cost outcomes and of a variable being missing were incorporated in the imputation model as recommended by White et al. [36]. The baseline variables predictive of clinical and cost outcomes and drop-out during follow-up were incorporated in the imputation model to enhance the precision of the model and to correct for possible bias. Age of the participants, age during the first depression, severity of the last depression, and treatment with AD at baseline were included in the imputation model for missing cost data. Residual depressive symptoms, age, age of the first depression, and previous number of depressive episodes were incorporated in the imputation model for missing outcome data regarding depression-free days. Gender, age, employment status,
residual depressive symptoms, age of the first depression, and number of previous depressive episodes were included in the imputation model for missing outcome data in terms of QALYs. To account for participants with extremely high costs resulting in unstable imputation estimates, winsorizing was used for the main analyses. Using winsorizing, extreme values are instead replaced by certain percentiles, in this case the 97.5th percentile as opposed to trimming in which the extreme values are merely deleted.

Costs and outcomes were used to calculate the incremental cost-effectiveness ratio (ICER) of M-CT relative to TAU alone [37]. The formula used for calculating the ICER is:

\[
\text{ICER} = \frac{(C_{\text{M-CT}} - C_{\text{TAU}})}{(QALY_{\text{M-CT}} - QALY_{\text{TAU}})}
\]

where, \(C_{\text{M-CT}}\) and \(C_{\text{TAU}}\) are the mean costs, and \(QALY_{\text{M-CT}}\) and \(QALY_{\text{TAU}}\) are the mean QALYs in M-CT and TAU, respectively. The ICER is interpreted as the additional costs per QALY gained when the M-CT is offered rather than TAU. The bootstrap method [38] was applied to account for the uncertainty in the economic evaluation by repeated random sampling with replacement from the original dataset. Seemingly unrelated regression equations (SURE) were bootstrapped (5000 times) to allow for correlated residuals of the cost and utility equations and to adjust for baseline differences in one of the sensitivity analyses. In each bootstrap step, the mean cost differences and the mean outcome difference were computed and these were plotted in the cost-effectiveness plane [39]. Finally, Cost-Effectiveness Acceptability Curves (CEACs) [40] were graphed. CEACs inform decision-makers on the likelihood that an intervention is deemed to be cost-effective given a range of willingness-to-pay ceilings for gaining and additional unit of health (i.e., gaining one QALY and gaining one depression-free day). The analyses were conducted using Stata.
Sensitivity analyses

Due to the amount of missing data, we used multiple imputation in the main analysis to handle missing data. To ascertain the robustness of our findings we performed several sensitivity analyses, each handling missing data in a different way. It should be noted that in the main analysis, 29 participants were not included since they dropped-out immediately after randomization and therefore no follow-up information was available. Nevertheless, we performed an additional sensitivity analysis in which all participants were included for a full-fledged intention-to-treat analysis. The main analysis was repeated again but now restricted to individuals for whom at least 50% of the cost data were available. A final analysis to evaluate the impact of dropout was based on complete cases. At baseline, we observed a slight imbalance between both conditions with respect to gender, severity of the last depressive episode, and baseline costs. Studies suggest that gender is not associated with relapse or recurrence but that severity of the last depressive episode might be [24]. Therefore, we repeated the main analysis but now adjusting for the small baseline imbalances in severity of the last depressive episode and baseline costs.

Results

Sample characteristics

Figure 1 displays the participant flow during the study. In total, 288 participants were eligible of whom 264 were randomized to either M-CT (n = 132) or TAU (n = 132). In total, 29 participants dropped-out immediately after randomization and 24 were lost to follow-up during the study. Overall, the baseline clinical and demographic characteristics of all participants (Table 1) and participants with any follow-up data were similar and equally distributed over the treatment conditions, suggesting no systematic bias owing to drop-out of the 29 individuals with no follow-up data. A slight imbalance with respect to gender, severity
of the last depressive episode, and baseline costs was found between the randomized conditions. Complete cost and effect data (available for all measurements) were available for 45 participants (17%). At least one measurement of cost data after baseline was available for 195 (75%) of the participants. For 129 participants (49%), at least half of the cost measurements were available.

Figure 1. CONSORT flow diagram over the 24 months follow-up.

Table 1. Sample characteristics by condition at baseline.

<table>
<thead>
<tr>
<th></th>
<th>M-CT (N = 132)</th>
<th>TAU (N = 132)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>45.6 (10.9)</td>
<td>47.1 (10.7)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>105/132 (79.5)</td>
<td>92/132 (69.7)</td>
</tr>
<tr>
<td>Country of birth The Netherlands, n (%)</td>
<td>116/131 (88.5)</td>
<td>121/131 (92.4)</td>
</tr>
<tr>
<td>Marital status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>39/131 (29.8)</td>
<td>32/132 (24.2)</td>
</tr>
<tr>
<td>Married or cohabiting</td>
<td>82/131 (62.6)</td>
<td>87/132 (65.9)</td>
</tr>
<tr>
<td>Divorced/widowed</td>
<td>10/131 (7.7)</td>
<td>13/132 (9.9)</td>
</tr>
<tr>
<td>Education, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary and/or secondary education</td>
<td>17/132 (12.9)</td>
<td>22/132 (16.7)</td>
</tr>
<tr>
<td>Vocational education</td>
<td>30/132 (22.7)</td>
<td>34/132 (25.8)</td>
</tr>
<tr>
<td>Higher education</td>
<td>85/132 (64.4)</td>
<td>76/132 (57.6)</td>
</tr>
<tr>
<td>Employed, n (%)</td>
<td>87/131 (66.4)</td>
<td>90/131 (68.7)</td>
</tr>
<tr>
<td>Treatment as Usual (TAU), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td>46/132 (34.8)</td>
<td>39/130 (30.0)</td>
</tr>
<tr>
<td>General practitioner</td>
<td>34/132 (25.8)</td>
<td>43/130 (33.1)</td>
</tr>
<tr>
<td>Specialized mental health (after)care</td>
<td>52/132 (39.4)</td>
<td>48/130 (36.9)</td>
</tr>
<tr>
<td>Treatment with antidepressants, n (%)</td>
<td>72/130 (55.4)</td>
<td>65/128 (50.8)</td>
</tr>
<tr>
<td>Previous episodes MDD, median (IQR)</td>
<td>4 (2.8)</td>
<td>4 (2.0)</td>
</tr>
<tr>
<td>Total HRSD, mean (SD)</td>
<td>3.7 (3.1)</td>
<td>3.4 (2.9)</td>
</tr>
<tr>
<td>Depressive symptoms (IDS-SR), mean (SD)</td>
<td>16.5 (10.3)</td>
<td>16.3 (9.7)</td>
</tr>
<tr>
<td>Severity past episode, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71/132 (53.8) Mild</td>
<td>37/132 (28.0)</td>
<td>25/132 (18.9)</td>
</tr>
<tr>
<td>Severe73/132 (55.3)</td>
<td>22/132 (16.7)</td>
<td>36/132 (27.3)</td>
</tr>
<tr>
<td>Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline utilities (EQ-5D-3L), mean (SD)</td>
<td>0.86 (0.12)</td>
<td>0.84 (0.17)</td>
</tr>
<tr>
<td>Baseline costs, mean (SD)</td>
<td>€1729 (€3699)</td>
<td>€1552 (€3216)</td>
</tr>
</tbody>
</table>
Costs

The various types of costs generated by both groups during the 24 months of the study are presented in Table 2. Presented costs were based on the data of participants for whom at least one cost measurement after the baseline assessment was available during the study. Mean costs of the M-CT intervention were €73 per participant. These costs were mainly related to the training and supervision of therapists, contacts between therapists and participants, and ICT costs (development and periodically upgrading the software and server costs). In both conditions, the costs of hospital admissions and outpatient care provided by mental health care services contributed considerably to the overall costs within the health care sector. Costs related to productivity losses had the largest impact on overall societal costs. Mean total costs cumulated over 24 months were €8,298 for M-CT and €7,296 for TAU. The per-participant incremental costs were €1,002 (€8,298–€7,296).

Table 2. Cumulative costs inside and outside the health care sector over 24 months

<table>
<thead>
<tr>
<th>Cost types</th>
<th>M-CT (n = 99)</th>
<th>TAU (n = 96)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean costs (SD)</td>
<td>%&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Health care costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobile CT</td>
<td>73 (19)</td>
<td>94</td>
</tr>
<tr>
<td>Psychiatrist</td>
<td>238 (688)</td>
<td>23</td>
</tr>
<tr>
<td>Psychologist</td>
<td>231 (893)</td>
<td>23</td>
</tr>
<tr>
<td>Psychotherapist</td>
<td>118 (548)</td>
<td>11</td>
</tr>
<tr>
<td>Social psychiatric nurse</td>
<td>12 (86)</td>
<td>3</td>
</tr>
<tr>
<td>Social worker</td>
<td>10 (69)</td>
<td>3</td>
</tr>
<tr>
<td>Self-help groups</td>
<td>3 (22)</td>
<td>3</td>
</tr>
<tr>
<td>Various MHC&lt;sup&gt;b&lt;/sup&gt; services</td>
<td>590 (1592)</td>
<td>30</td>
</tr>
<tr>
<td>Polyclinic care</td>
<td>240 (592)</td>
<td>46</td>
</tr>
<tr>
<td>CAD&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-</td>
<td>0</td>
</tr>
</tbody>
</table>
The costs are displayed for participants with at least one cost measurement during follow-up.

aPercentage of participants using the cost types concerned
bMental health care services
cConsultation office for Alcohol and Drug addiction

Effects

The mean number of depression-free days within the 24 months of the study was 661 in M-CT and 656 in TAU. The incremental effectiveness of 5 days was not statistically significant (b = 5.6, SE_b = 13.0, t = 0.43, P = 0.668). In addition, no statistically significant differences in QALYs gains were found between M-CT and TAU (mean QALY for both M-CT and TAU was 1.65, b = 0.004, SE_b = 0.02, t = 0.18, P = 0.857).

Economic evaluation

According to the main analysis, M-CT resulted in slightly better health outcomes (an extra 5.6 gain in depression-free days and a 0.004 QALY gain), but these health gains were achieved at higher costs (€1,008). For both health outcomes, most of the bootstrapped ICERs were located in the North-East quadrant (55.5% for depression-free days and 46.5% for QALYs), indicating that the probability that M-CT is deemed cost-effective depends on the willingness-
to-pay for an additional health gain (see Figure 2 and 3). When the willingness-to-pay per additional depression-free day is zero, M-CT has approximately a 40% probability to be cost-effective. When the willingness-to-pay per additional gain in depression-free days increases, the probability that M-CT is cost-effective also increases but does not rise above 65%. For QALYs, increased willingness-to-pay only leads to slight increases in the probability that M-CT will be considered cost-effective and the probability that M-CT is cost-effective did not rise above 40%.

**Figure 2.** Incremental cost-effectiveness plane (left) and cost-effectiveness acceptability curve (right) for the 5000 bootstrapped incremental costs per depression-free day gained

PE-line: line which represents the point estimate of the ICER (average cost/effect of bootstrap replications).
Figure 3. Incremental cost-effectiveness plane (left) and cost-effectiveness acceptability curve (right) for the 5000 bootstrapped incremental costs per QALY gained

PE-line: line which represents the point estimate of the ICER (average cost/effect of bootstrap replications).

Sensitivity analyses

Table 3 displays the sensitivity analyses. The sensitivity analysis including all randomized participants \((n = 289)\) overall yielded similar results. When taking into account participants for whom at least 50% of the data were available, TAU dominated M-CT in terms of depression-free days and results were roughly similar to the main analysis for QALYs. In the complete case analysis, TAU dominated M-CT. Adjustments for imbalanced baseline variables yielded similar results.
Table 3 Sensitivity analyses with all estimates based on 5000 bootstrap replications

<table>
<thead>
<tr>
<th>Analysis</th>
<th>N</th>
<th>Incremental costs</th>
<th>Incremental effects</th>
<th>Mean ICER&lt;sup&gt;a&lt;/sup&gt;</th>
<th>NE %</th>
<th>SE % (dominant)</th>
<th>SW %</th>
<th>NW % (inferior)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cost-effectiveness, depression-free days</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Main analysis&lt;sup&gt;b&lt;/sup&gt;</td>
<td>235</td>
<td>€1,008</td>
<td>5.6</td>
<td>€179</td>
<td>55.5</td>
<td>11.6</td>
<td>2.6</td>
<td>30.2</td>
</tr>
<tr>
<td>Main analysis all participants&lt;sup&gt;c&lt;/sup&gt;</td>
<td>264</td>
<td>€788</td>
<td>5.6</td>
<td>€140</td>
<td>51.7</td>
<td>15.5</td>
<td>3.8</td>
<td>29.1</td>
</tr>
<tr>
<td>≥50% follow-up Data</td>
<td>129</td>
<td>€1,562</td>
<td>-34.7</td>
<td>(dominated)</td>
<td>1.8</td>
<td>1.3</td>
<td>20.3</td>
<td>76.6</td>
</tr>
<tr>
<td>Complete case</td>
<td>45</td>
<td>€2,086</td>
<td>-51.7</td>
<td>(dominated)</td>
<td>1.8</td>
<td>1.3</td>
<td>20.3</td>
<td>76.6</td>
</tr>
<tr>
<td><strong>Cost-utility, QALYs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Main analysis&lt;sup&gt;b&lt;/sup&gt;</td>
<td>235</td>
<td>€1,008</td>
<td>0.004</td>
<td>€230,816</td>
<td>46.5</td>
<td>11.2</td>
<td>3.0</td>
<td>39.3</td>
</tr>
<tr>
<td>Main analysis all participants&lt;sup&gt;c&lt;/sup&gt;</td>
<td>264</td>
<td>€1,033</td>
<td>0.02</td>
<td>€53,583</td>
<td>63.9</td>
<td>16.5</td>
<td>1.6</td>
<td>18.1</td>
</tr>
<tr>
<td>≥50% follow-up Data</td>
<td>129</td>
<td>€1,562</td>
<td>0.02</td>
<td>€87,676</td>
<td>48.8</td>
<td>2.6</td>
<td>29.6</td>
<td></td>
</tr>
<tr>
<td>Complete case</td>
<td>45</td>
<td>€2,086</td>
<td>-0.04</td>
<td>(dominated)</td>
<td>15.6</td>
<td>11.9</td>
<td>15.7</td>
<td>56.8</td>
</tr>
</tbody>
</table>

<sup>a</sup>Mean incremental cost-effectiveness ratio of the 5000 bootstrap replications

<sup>b</sup>Main analysis using multiple imputation with predictive mean matching, excluding the 29 participants with no follow-up data

<sup>c</sup>The main analysis, but now with all participants including the 29 participants without follow-up data
Discussion

Principal results and comparison with prior work

The current study was the first to evaluate the cost-effectiveness and cost-utility of an internet-based relapse prevention program for recurrent MDD. The results of the current study suggest that M-CT added to TAU is not cost-effective compared to TAU alone over a 24-month period.

The mean total societal costs during the 24-month period were slightly higher for M-CT. The results revealed that the total costs in both conditions were dominated by losses in productivity, which is consistent with the literature [41, Biesheuvel-Leliefeld et al., under review]. Krol et al. [41] found that choices made regarding the inclusion or exclusion of indirect costs influence cost-effectiveness studies to a great extent. As MDD is a disorder with extensive losses in worker productivity [4-7,41], we choose to perform the analyses from a societal perspective including both direct and indirect costs. Our main analysis showed that participants using M-CT had slightly more depression-free days (5.6 days) and better QALYs (0.004) compared to TAU achieved at higher costs (€1,008). The probability that M-CT was cost-effective in terms of depression-free days and QALYs was dependent on the willingness-to-pay for an additional health gain. For depression-free days, a substantial investment had to be made before reaching an acceptable probability that M-CT was deemed cost-effective. For QALYs, a substantial investment had to be made but the probability that M-CT was cost-effective did not rise above 40%. We conclude that adding M-CT to TAU is not a cost-effective strategy compared to TAU alone. The results of the sensitivity analyses were partly inconsistent with the main analysis and will be further discussed at the limitations section.

The results contrast with our expectations based on the positive short-term results of M-CT [42] and with the promising findings of Holländare regarding the internet-based relapse prevention therapy in partially remitted individuals [19]. Moreover, the results contrast with
the long-term effectiveness of face-to-face PCT [26-28,43, De Jonge et al., submitted] and
with PCT administered as bibliotherapy with therapist support [44]. As reported elsewhere
[20], treatment adherence in the current study was comparable to other studies (in total, 90 out
of 132 (68.2%) finished at least five lessons) [15] and therefore we believe this did not
explain the results. Our short-term clinical results demonstrated a positive effect of M-CT on
residual depressive symptoms during the first months compared to TAU [42], whereas our
long-term results showed no protective effects of M-CT on cumulative relapse/recurrence
rate, number of depressive relapses/recurrences, and depressive symptoms after 24 months
[20]. Therefore, we hypothesize that M-CT might generate better effects at lower costs during
the first months and hence might be more cost-effective compared to TAU but that the costs
and effects become less favorable for M-CT in the long run. This hypothesis is consistent with
the systematic review of So et al. [45] that found short-term effects of internet-based
treatments for MDD, but no effects beyond 6 months post-treatment. However, a recent
systematic review on the long-term effects of internet-based guided cognitive behavioral
therapy showed enduring effects for several disorders [46]. We hypothesize that more
therapist-support and/or booster sessions are needed for M-CT to become more cost-effective
in the long term. In the current study, minimal therapist support was enlisted by the
participants, i.e., a mean total therapist time of only 17.3 minutes (range = 0-70) per
participant. Several systematic reviews and meta-analyses showed that internet-based
interventions are especially effective when provided with therapist support [13,15,16].
Therapist guidance also seems an important factor in economic evaluations of internet-based
interventions. A recent systematic review on economic evaluations of internet- and mobile-
based interventions for the treatment and prevention of depression concluded that the internet-
based interventions that were likely to be cost-effective were all guided interventions whereas
the unguided interventions were not likely to be cost-effective or ambiguous [47]. However, it
is important to note that for most of these guided interventions a considerable investment was needed in order to reach an acceptable probability that the intervention was deemed cost-effective. In their systematic review on the cost-effectiveness of internet-based interventions for a wide range of mental health disorders, Donker et al. [48] also highlighted that the most robust evidence in terms of cost-effectiveness was found for guided interventions. A recent individual-participant data meta-analysis on the cost-effectiveness of guided internet-based interventions for depression based on five studies concluded that considerable investments had to be made for an acceptable probability that the intervention would be cost-effective compared to controls in terms of treatment response and depressive symptoms and that for QALYs this probability was low at the widely used willingness-to-pay-threshold [49].

Differences between the systematic reviews and meta-analysis might be caused by differences in methodology, control group, and/or differences in when an intervention is perceived as cost-effective. For example, in the systematic review of Paganini et al. [47], studies examining only direct health care costs were also included and four out of the seven studies classified as cost-effective used a waitlist control group as comparator, whereas in the meta-analysis of Kolovos et al. [49], only studies were included that also took into account productivity losses and only one study included a waitlist control group.

Thus, more information is needed under which circumstances internet-based treatments are effective and cost-effective on short-term and long-term outcomes. In addition, more information is needed under which circumstances face-to-face or other forms of PCT are cost-effective. To date, one study examined the cost-effectiveness of PCT administered as guided bibliotherapy for remitted recurrently depressed individuals [Biesheuvel-Leliefeld et al., under review] and another study examined the cost-effectiveness of PCT in remitted recurrently depressed individuals that had received acute-phase CT [De Jonge et al., in preparation]. Both studies concluded that investments had to be made for an acceptable
probability that the intervention would be cost-effective in terms of recurrences. For QALYs, substantial investments had to be made but probabilities that the intervention would be cost-effective remained low.

**Limitations**

Some limitations of this study are important to acknowledge. First, cost data were collected with a self-report questionnaire approximately every 3 months during the 24-month follow-up and therefore a substantial amount of participants missed one or more measurement. To deal with missing data, multiple imputation, which is a recommended strategy to handle missing data in cost-effectiveness studies performed alongside randomized controlled trials [50], was used in our main analysis. We can assume the data were at least partly missing at random since baseline characteristics predicted whether the data were missing. Nevertheless, the missing completely at random assumption cannot be proved and it is possible data were missing not at random because drop-out could be related to depressive symptom severity. Because of the amount of missing data, we did not want to rely on a single imputation technique and therefore performed several sensitivity analyses that each handled missing data in a different way. The main analysis, the analysis including all participants, and the analysis incorporating participants for whom at least 50% of the data were available (the latter only regarding QALYs) showed similar results. The analysis including participants with at least 50% data (regarding depression-free days) and complete cases showed higher costs and worse outcomes for M-CT compared to TAU. Multiple imputation is preferred over a complete case analysis because of the potential selection bias that might occur due to missing values. The results of the complete cases and cases with at least 50% of the data do suggest a possible selection bias in drop-out, which is also suggested when inspecting a baseline table displaying
only the complete cases and cases with 50% of the data. Altogether, we regard our main analysis as primary.

Second, the data were obtained in the Netherlands and therefore generalizability into other countries with other treatment settings is questionable. Third, the cost data and data for the cost-utility analysis were based on retrospective self-report questionnaires which may have affected the reliability. The TiC-P has shown to be a reliable and valid questionnaire for collecting cost data [52]. However, the EQ-5D might be subjected to a possible ceiling effect when estimating changes in QALYs for this group of remitted individuals. Moreover, the EQ-5D refers to the current health state and therefore does not capture all relapses/recurrences during the 24 months of the study.

Conclusions

Although the effectiveness of internet-based therapy for depression is currently established, only a few studies examined the cost-effectiveness of these interventions [for systematic reviews, see 17,18,46,48,53,54]. Altogether, we conclude that adding internet-based M-CT to TAU is not an effective or cost-effective strategy to prevent relapse and recurrence. Future studies should examine the long-term effectiveness of internet-based interventions and the optimal dosage of guidance by therapists. MDD is highly recurrent [2] and one of the leading causes of disability [1,3]. Therefore it is important that future studies continue to examine highly accessible, scalable and (potentially) cost-effective interventions to treat depression including interventions that prevent recurrence. These studies are needed to inform decisions in mental health care. Since treatment effects can manifest differently over time [44], it is important that these cost-effectiveness studies on face-to-face and internet-based interventions include long follow-up periods.
Acknowledgments

We are grateful to all participants, recruitment sites, therapists, (PhD) students, and volunteers that contributed to this study. The Netherlands Organisation for Health Research and Development (ZONMW, Department of Disease Management and Chronic Illnesses, grant number 300020014) funded this RCT. The funder did not have a role in the study design, the data collection procedure, analyzing, interpreting, or publication of the results. This article has partly been written by Claudi L.H. Bockting as part of a fellowship at the Netherlands Institute for Advances Study in the Humanities and Social Science Study (NIAS).

Nicola S. Klein was involved in the data collection, the interpretation of the data, and in drafting and critically revising the manuscript. Claudi L. H. Bockting was involved in the design, development of M-CT, data collection, interpretation of the data and critically revising the manuscript. Ben Wijnen was involved in the analysis and interpretation of the data and in drafting and critically revising the content of the manuscript. Gemma D. Kok was involved in piloting M-CT, recruitment, data collection, interpretation of the data, and in critically revising the manuscript. Evelien van Valen was involved in the development of M-CT and supervision of therapists and critically revising the content of the manuscript. Huibert Burger, Heleen Riper, Pim Cuijpers, Jack Dekker, Filip Smit and Colin van der Heiden were involved in the design of the study and in critically revising the manuscript. All authors have significantly contributed to the manuscript and have approved the final version.

Conflicts of interest

Claudi L.H. Bockting and Evelien van Valen developed M-CT that was integrated in the platform of the Trimbos Institute in collaboration with Filip Smit. No other disclosures are reported.
Multimedia Appendix 1: CONSORT-EHEALTH checklist

References


40. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves - Facts,


**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>antidepressants</td>
</tr>
<tr>
<td>CEAC</td>
<td>cost-effectiveness acceptability curves</td>
</tr>
<tr>
<td>DSM</td>
<td>Diagnostic and Statistical Manual of Mental Disorders</td>
</tr>
<tr>
<td>ICER</td>
<td>incremental cost-effectiveness ratio</td>
</tr>
<tr>
<td>M-CT</td>
<td>mobile cognitive therapy</td>
</tr>
<tr>
<td>MDD</td>
<td>major depressive disorder</td>
</tr>
<tr>
<td>PCT</td>
<td>preventive cognitive therapy</td>
</tr>
<tr>
<td>QALY</td>
<td>quality-adjusted life year</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>SCID</td>
<td>Structured Clinical Interview for DSM Disorders</td>
</tr>
<tr>
<td>TAU</td>
<td>treatment as usual</td>
</tr>
</tbody>
</table>